Portfolio Companies
4Octant
Therapeutics company Octant raises $80M in Series B funding
Nautilus Biotechnology
Madrona announces investment in Nautilus Biotechnology, a company at the intersection of innovation in biotechnology.
TwoXAR
TwoXAR raises Series A to accelerate drug discovery timelines using advanced technology
Freenome
Andreessen Horowitz invests in Freenome through its new bio fund
Recent Articles
20Bioluminescence Ventures Emerges from Stealth with $477M AUM - Business Wire
Bioluminescence Ventures has officially emerged from stealth mode, announcing $477 million in assets under management. The venture firm goes public with a significant fund size, signaling its readiness to actively invest in its target sectors.
11/1/2023
Therapeutics Company Octant Secures $80 Million In Series B Funding - Pulse 2.0
Octant, a therapeutics company, has successfully raised $80 million in Series B funding, marking a significant milestone in its growth and drug development efforts.
4/27/2022
Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson Sonsini
Wilson Sonsini advised Octant on its $80 million Series B financing and a strategic partnership with Bristol Myers Squibb, supporting the biotech company's growth and drug discovery initiatives.
4/22/2022
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership - Fierce Biotech
Octant has secured $80M in funding and formed a partnership with Bristol Myers Squibb to advance its next-generation drug discovery platform into a new era of biopharmaceutical development.
4/21/2022
Who is Chris Dixon? - Fortune
An overview of Chris Dixon, a prominent venture capitalist and general partner at Andreessen Horowitz (a16z), known for his influential role in crypto and Web3 investments.
4/21/2022
Octant Scores $80M in Series B Funds, Partnership with BMS - BioSpace
Octant has secured $80 million in Series B funding and announced a strategic partnership with Bristol Myers Squibb (BMS), marking a significant milestone for the biotech company.
4/21/2022
Catalio Capital Management Leads $80M Series B in Octant - citybiz
Catalio Capital Management has led an $80 million Series B funding round in Octant, a biotech company. This significant investment highlights growing interest in the biotechnology sector and Octant's potential in drug discovery and development.
4/21/2022
BMS joins Octant’s $80M financing and signs on as a drug discovery partner - MedCity News
Bristol Myers Squibb (BMS) has joined Octant's $80M financing round and established a drug discovery partnership with the biotech company.
4/21/2022
The VC who helped spin up Andreessen Horowitz's bio fund just raised $50 million for a third solo fund - Business Insider
A venture capitalist who played a key role in launching Andreessen Horowitz's bio fund has successfully raised $50 million for their third independent fund, marking continued growth in solo VC activity.
6/3/2021
Biotech's top 10 money raisers of 2020 - Fierce Biotech
Fierce Biotech highlights the top 10 biotech companies that raised the most funding in 2020, showcasing the year's biggest financial achievements in the biotechnology sector.
3/22/2021
Genentech taps Stanford University spinout for AI drug discovery partnership - Fierce Biotech
Genentech has partnered with a Stanford University spinout company to advance AI-driven drug discovery, combining cutting-edge artificial intelligence with biopharmaceutical expertise.
10/19/2020
Embracing the Intersections of Innovation: Our Investment in Nautilus Biotechnology - Madrona
Madrona announces its investment in Nautilus Biotechnology, a company at the intersection of innovation in life sciences and technology, highlighting the firm's commitment to groundbreaking biotech ventures.
5/20/2020
Venture-Capital Investors Share Their Healthcare Predictions for 2020 - Business Insider
Venture-capital investors share their key predictions for the healthcare industry in 2020, highlighting emerging trends and investment opportunities in the sector.
12/19/2019
Dog cancer treatment startup raises $5 million from Andreessen Horowitz and others - TechCrunch
A startup focused on cancer treatment for dogs has raised $5 million in funding from prominent investors including Andreessen Horowitz, aiming to advance veterinary oncology solutions.
1/23/2019
TwoXAR announces Series A in quest to collapse drug discovery timelines - MIT Sloan
TwoXAR, an AI-driven drug discovery company, announced its Series A funding round aimed at significantly reducing the time required to discover and develop new drugs using artificial intelligence.
3/21/2018
Artificial intelligence firm twoXAR raises $10M for partnering drive - Fierce Biotech
AI-driven drug discovery company twoXAR has raised $10 million to accelerate its partnering strategy, aiming to collaborate with pharmaceutical companies to advance drug candidates.
3/19/2018
twoXAR Raises $10M in Series A Financing - FinSMEs
twoXAR has successfully raised $10 million in a Series A financing round, marking a significant milestone for the company as it advances its operations and growth strategy.
3/19/2018
Andreessen Horowitz Is Digging Deeper Into Biotech - BuzzFeed News
Venture capital firm Andreessen Horowitz is expanding its presence in the biotech sector, signaling a deeper commitment to life sciences and biotechnology investments.
6/21/2017
Emerging Pharma Leaders: Andrew A. Radin and Andrew M. Radin - Pharmaceutical Executive
Pharmaceutical Executive highlights Andrew A. Radin and Andrew M. Radin as emerging leaders in the pharmaceutical industry, recognizing their notable contributions and potential impact on the sector.
10/3/2016
Andreessen Horowitz Invests in Freenome Through New Bio Fund - Business Insider
Andreessen Horowitz has invested in Freenome through its newly established bio-focused fund, signaling the firm's growing interest in the biotechnology and life sciences sector.
6/9/2016
Investment Signals
13Biotech companies demonstrated significant capital raising activity in 2020, indicating strong investor interest in the sector during the pandemic period.
twoXAR successfully raised $10M in Series A financing, indicating investor confidence in their healthtech platform targeting financial SMEs.
Bioluminescence Ventures launches with $477M in assets under management, signaling significant capital deployment in the biotech sector.
Octant secured a partnership with Bristol Myers Squibb, a major pharmaceutical company, validating its technology and market relevance.
Octant raised $80 million in Series B funding, indicating strong investor confidence in the company's biotech capabilities and commercial potential.
Andreessen Horowitz is increasing its focus and investment activity in the biotech sector, signaling confidence in the space's long-term potential.
VCs are making healthcare-focused predictions for 2020, indicating active investor focus on the healthtech sector.
Large pharma (BMS) is actively investing in and partnering with biotech companies for drug discovery capabilities, suggesting a thesis around outsourced discovery platforms.
BMS participates in Octant's $80M financing round and establishes a strategic drug discovery partnership, signaling confidence in the company's platform.
The track record and fundraising success of this VC suggests sustained investor confidence in biotech as a viable investment thesis, particularly for experienced operators launching new funds.
A prominent VC investor with significant experience from a16z's bio fund has successfully raised $50 million for their third independent fund, signaling continued confidence in biotech investment opportunities.
Octant, a therapeutics company, successfully raised $80 million in Series B funding, indicating investor confidence in their drug development platform.
Catalio Capital Management led an $80M Series B funding round for Octant, indicating significant capital deployment in fintech sector.